Investigational drug · Phase 2
SLN124
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Polycythemia Vera.
Phase 2Last checked: Nov 19, 2026Latest source record: Dec 19, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "SLN124"
First trial start
2023
Jan 26, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SLN124", any sponsor or status.
Conditions studied
As listed on its trial records.
- Polycythemia Vera
Approved drugs for the same conditions: Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "SLN124" as an intervention, largest first.
- Study to Assess SLN124 in Patients With Polycythemia VeraActive, not recruiting
Silence Therapeutics plcIndustry
NCT05499013 · 69 participants · Start Jan 26, 2023 · Primary completion Sep 2026
Drug: SLN124; Placebo · For: Polycythemia Vera
Sites: Hammond, Louisiana; Buffalo, New York; New York, New York · 28 sites in all
Silence Therapeutics plcIndustry
NCT04718844 · 44 participants · Start Apr 14, 2021 · Primary completion May 23, 2023
Drug: SLN124; Placebo · For: Non-transfusion-dependent Thalassemia; Low Risk Myelodysplastic Syndrome; Very-Low Risk Myelodysplastic Syndrome
Sites: Düsseldorf, Germany; Leipzig, Germany; Haifa, Israel · 20 sites in all
- A Phase 1 Study to Evaluate the Safety, Tolerability, PK and PD of SLN124 in Healthy VolunteersCompleted
Silence Therapeutics plcIndustry
NCT04559971 · 24 participants · Start Sep 3, 2020 · Primary completion Mar 23, 2021
Drug: SLN124; Placebo · For: Healthy Volunteers
Sites: London, United Kingdom
Silence Therapeutics plcIndustry
NCT04176653 · 0 participants · Start Aug 20, 2019 · Primary completion Sep 30, 2021
Drug: SLN124 is a GalNAc conjugated double stranded fully modified siRNA. Sodium chloride 0.9% w/v is used as Placebo · For: Non-transfusion-dependent Thalassemia; Low Risk Myelodysplastic Syndrome
Sites: Kyustendil, Bulgaria; Pleven, Bulgaria; Sofia, Bulgaria · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Therapeutic Silencing of Tmprss6 Reduces Iron-Induced Inflammation and Prolongs Survival in MDS Mice.
Vilcassim S, Pholngam N, Thubthed R, et al. · Am J Hematol 2026
- SLN124, a GalNAc conjugated 19-mer siRNA targeting tmprss6, reduces plasma iron and increases hepcidin levels of healthy volunteers.
Porter JB, Scrimgeour A, Martinez A, et al. · Am J Hematol 2023
- SLN124, a GalNac-siRNA targeting transmembrane serine protease 6, in combination with deferiprone therapy reduces ineffective erythropoiesis and hepatic iron-overload in a mouse model of β-thalassaemia.
Vadolas J, Ng GZ, Kysenius K, et al. · Br J Haematol 2021
- SLN124, a GalNAc-siRNA Conjugate Targeting TMPRSS6, Efficiently Prevents Iron Overload in Hereditary Haemochromatosis Type 1.
Altamura S, Schaeper U, Dames S, et al. · Hemasphere 2019
Also in development for Polycythemia Vera
- BomedemstatMK-3543, IMG-7289Phase 35 trials
Merck & Co. · Polycythemia Vera, Essential Thrombocythemia, Thrombocythemia, Essential
- KRT-232NavtemadlinPhase 34 trials
Kartos Therapeutics, Inc. · Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
- SapablursenISIS 702843, ONO-0530Phase 32 trials
Ono Pharmaceutical Co., Ltd. · Polycythemia Vera, Phlebotomy Dependent Polycythemia Vera
- AG-236Phase 31 trial
Agios Pharmaceuticals, Inc. · Polycythemia Vera
- JBI-802Phase 21 trial
Jubilant Therapeutics Inc. · Essential Thrombocythemia (ET), Polycythemia Vera
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.